The News Review:

- Laura Ann Crittenden
- Research and Markets: Booming Clinical Trials Market in India
- INC Research to Acquire Global Clinical Development Unit of MDS …
- Top Medical Research Centers Form Velos Advisory Group for Service …
- » Clinical Research Associate

Laura Ann Crittenden
Mansfield News Journal
She also did post graduate work at Ashland University. During her career she worked as Research Project Administrator at Texas Tech University Health Sciences Center Lubbock Texas; followed by Research Data Manager at The Center for Prostate Disease Research Wright Patterson Air Force Base Dayton hio. She became a Certified Clinical Research Professional (CCRP) in 2003 and worked as Clinical Research Coordinator at University of Texas Southwestern Medical Center. At the time of her death she was working as a Senior Clinical Research Associate for i3 research and received the honor of “utstanding Employee of the Year” in 2008. Pride in her profession and pride and love for her family dominated her life. She is survived by her son Patrick R. Nixon of Denton Texas; and her daughter Heather A.

Research and Markets: Booming Clinical Trials Market in India
Business Wire (press release)
Research and Markets: Booming Clinical Trials Market in India. researchandmarkets.
Related from Ytbao: David A Wan | India is key market in Asia-Pacific region

INC Research to Acquire Global Clinical Development Unit of MDS …
Business Wire (press release)
” The acquisition of MDS Pharma Services Phase II-IV operation is expected to deepen INC Research’s therapeutic expertise with its leadership in vaccine respiratory cardiovascular and endocrinology clinical research and extend its global presence in emerging markets including South America Asia Pacific and Africa. The combination of such complementary businesses and integration of operations through INC Research’s Trusted Process® will enable INC Research to enhance its global services to deliver cost-effective results with reduced variability. With nearly 800 clinical research staff globally MDS Pharma Services Phase II-IV operation has conducted more than 700 Phase II-IV clinical projects involving more than 42000 sites and nearly 300000 patients in a wide range of therapeutic areas from 2000 to 2008. The MDS Pharma Services Phase II-IV operation has been consistently ranked as one of the Top 5 CRs in the CenterWatchSM survey of investigators from 2001-2008 in various service attributes; its therapeutic expertise complements INC Research’s reputation in managing clinical research on the central nervous system (CNS) infectious diseases and oncology. This acquisition is expected to create a broader spectrum of service offerings and capabilities for INC Research to meet customer demands across the globe. The acquisition will expand INC Research’s global footprint to nearly 2000 employees and operations in 40 countries. “MDS Pharma Services Phase II-IV operations have been significantly strengthened in recent years through global expansion and investments in process improvements that have made it an attractive acquisition target” said David Spaight president of MDS Pharma Services.

Top Medical Research Centers Form Velos Advisory Group for Service …
PR Newswire (press release)
Velos eResearch is deployed for clinical research in all parts of the healthcare enterprise and supports a broad diversity of clinical departments and functional needs. The system fundamentally improves the way data is collected organized and shared. A pure Internet technology platform Velos eResearch harnesses advanced powers of the Internet to enable research sites sponsors and patients to participate in a secure integrated system platform. System users are freed of redundant data entry and related time delays associated with most clinical research today. With emphasis on workflow Velos integrates the clinical administrative and financial information needs of research management.

» Clinical Research Associate
Hays Pharma
com and thinks you would be interested. You can view more opportunities at hayspharma. comFriend email addressSend emailRelated NewsNew drug could ‘revolutionise’ tuberculosisA study has revealed that patients who suffer from a severe form of tuberculosis could soon receive.